Accuray (ARAY) News Today

Accuray Incorporated (NASDAQ:ARAY) shares reacted to a mix of quarterly results, analyst commentary and earnings forecasts. Investors focused on Q4 fiscal 2025 performance—where revenue topped estimates but EPS fell short—as well as fresh guidance and price-target revisions from major brokerage firms.

• Positive Sentiment: BTIG Research reiterated its “buy” rating on ARAY and lifted the price target from $4.00 to $5.00, implying more than 250% upside from recent levels. Accuray price target raised by BTIG
• Positive Sentiment: The Q4 2025 earnings call highlighted resilient growth amid geopolitical headwinds, with management pointing to solid adoption of its precision-medicine systems in key markets. Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Roth Capital published Q1–Q4 2027 EPS estimates for Accuray, forecasting losses of ($0.02) and ($0.01) in the first half, and modest profitability in H2. Roth Capital EPS estimates
• Neutral Sentiment: Accuray reported in-line Q4 EPS of $0.01 and topped revenue estimates with $127.5 million versus $123.8 million consensus; shares nevertheless edged lower after the release. Accuray posts in-line Q4 earnings
• Neutral Sentiment: TipRanks characterized the fiscal 2025 results as mixed, noting a slight revenue beat offset by the EPS shortfall. Reports Mixed Fiscal 2025 Results
• Negative Sentiment: Accuray’s Q4 EPS of $0.01 missed the $0.03 consensus by $0.02, and the company posted a negative net margin of 0.35%, which dampened investor sentiment. View Press Release
• Negative Sentiment: Zacks highlighted that product sales suffered from tariffs and regional demand softness, contributing to a year-over-year revenue decline and the stock’s underperformance. Earnings Miss Weighs on Shares